Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers
Authors
Michael Nauck•Markus Heimesaat•Wolff Schmiegel
Journal
The Journal of Clinical Endocrinology & Metabolism
Published
March 1, 2002
Abstract
Glucagon-like peptide 1 (GLP-1) and analogues are being evaluated as a new therapeutic principle for the treatment of type 2 diabetes. GLP-1 suppresses glucagon secretion, which could lead to disturbances of hypoglycemia counterregulation. This has, however, not been tested.
Supporters
Support the authors with ResearchCoin
Topics
DOI
License
Unknown License